
Iovance Biotherapeutics (IOVA) Stock Forecast & Price Target
Iovance Biotherapeutics (IOVA) Analyst Ratings
Bulls say
Iovance Biotherapeutics is attractive because its lead TIL therapy is showing clinically differentiated durability and depth of response, with 3Q26 revenue of $122MM, melanoma ORR of 62.5% and CR rate of 29.2%, and NSCLC responses still ongoing in 9 of 17 responders. It also has a meaningful commercial tailwind, as 3Q26 results beat estimates, cash and equivalents were $382.3MM, and the company raised FY26 revenue guidance to $410MM-$420MM on strong AMTAGVI and Proleukin demand. The outlook is further supported by an expanding authorized treatment center network above 100 sites, faster manufacturing turnaround near 30 days, and multiple upcoming catalysts in ESMO'26, 4Q26, and 2027 that could broaden adoption across solid tumors.
Bears say
Iovance Biotherapeutics is viewed negatively because lifileucel’s NSCLC dataset showed only stable efficacy as it expanded, with ORR at 24.6% (17/69) versus 25.6% previously, while durability looks weaker as an estimated 4 of 13 responses ended within six months and the company withheld updated median DOR, PFS, and OS. The slower durability profile, including an observed median DOR of about 10 months in 2026 versus 12 months in 2025 and a greater frequency of early progression, raises questions about the impact of the new lymphodepletion regimen and the strength of the response tail despite several cases lasting beyond two years. In addition, the company still faces meaningful regulatory risk from pending FDA and EMA approvals and competitive pressure from approved melanoma therapies and emerging CAR-T approaches in solid tumors, which could limit commercial success.
This aggregate rating is based on analysts' research of Iovance Biotherapeutics and is not a guaranteed prediction by Public.com or investment advice.
Iovance Biotherapeutics (IOVA) Analyst Forecast & Price Prediction
Start investing in Iovance Biotherapeutics (IOVA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Iovance Biotherapeutics (IOVA) Forecast
Iovance Biotherapeutics (IOVA) Analyst Forecast & Price Prediction
Start investing in Iovance Biotherapeutics (IOVA)
Order type
Buy in
Order amount
Est. shares
0 shares